GlaxoSmithKline Pharmaceuticals Ltd
GLAXOGlaxoSmithKline Pharmaceuticals Ltd
GLAXO
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 58.44 | 22.19 | 1.37% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.53 | 6.56 | 0.52% |
Forecast & Ratings
Detailed Forecast from 4 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
GlaxoSmithKline Pharmaceuticals is a pharmaceutical company engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company develops a range of products in pharmaceuticals, vaccines and consumer healthcare.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,977.08 | 3,029.71 | 2,943.80 | 3,279.21 | 3,850.20 | 3,143.70 | 4,700.86 | 3,365.83 | 3,595.99 | 3,695.69 | ||||||||||
Raw Materials | 1,377.57 | 1,314.38 | 1,299.24 | 1,332.46 | 1,343.30 | 1,294.88 | 1,340.62 | 1,215.92 | 1,398.25 | 2,696.22 | ||||||||||
| Power & Fuel Cost | 25.97 | 27.82 | 26.44 | 27.94 | 33.36 | 26.08 | 27.83 | 29.60 | 29.64 | |||||||||||
| Employee Cost | 443.37 | 483.01 | 523.40 | 537.20 | 628.55 | 616.16 | 610.23 | 594.99 | 624.39 | |||||||||||
| Selling & Administrative Expenses | 333.63 | 373.99 | 358.84 | 381.41 | 376.88 | 242.05 | 343.67 | 370.30 | 374.73 | |||||||||||
| Operating & Other expenses | 192.78 | 292.00 | 157.73 | 268.39 | 1,073.35 | 357.54 | 215.32 | 248.00 | 281.31 | |||||||||||
EBITDA | 603.76 | 538.51 | 578.15 | 731.81 | 394.76 | 606.99 | 2,163.19 | 907.02 | 887.67 | 999.47 | ||||||||||
| Depreciation/Amortization | 24.95 | 27.08 | 37.99 | 48.59 | 82.68 | 78.60 | 68.19 | 65.77 | 69.68 | 68.48 | ||||||||||
| PBIT | 578.81 | 511.43 | 540.16 | 683.22 | 312.08 | 528.39 | 2,095.00 | 841.25 | 817.99 | 930.99 | ||||||||||
| Interest & Other Items | 0.42 | 0.25 | 0.19 | 0.55 | 6.34 | 3.53 | 2.00 | 1.81 | 1.80 | 1.73 | ||||||||||
| PBT | 578.39 | 511.18 | 539.97 | 682.67 | 305.74 | 524.86 | 2,093.00 | 839.44 | 816.19 | 929.26 | ||||||||||
| Taxes & Other Items | 202.25 | 174.38 | 189.24 | 237.27 | 212.55 | 166.72 | 398.28 | 228.76 | 226.23 | 254.23 | ||||||||||
| Net Income | 376.14 | 336.80 | 350.73 | 445.40 | 93.19 | 358.14 | 1,694.72 | 610.68 | 589.96 | 675.03 | ||||||||||
| EPS | 22.20 | 19.88 | 20.70 | 26.29 | 5.50 | 21.14 | 100.04 | 36.05 | 34.83 | 39.85 | ||||||||||
| DPS | 25.00 | 15.00 | 17.50 | 20.00 | 40.00 | 30.00 | 90.00 | 32.00 | 32.00 | 32.00 | ||||||||||
| Payout ratio | 1.13 | 0.75 | 0.85 | 0.76 | 7.27 | 1.42 | 0.90 | 0.89 | 0.92 | 0.80 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Ltd | 66.86 | 22.19 | 1.37% |
| Sun Pharmaceutical Industries Ltd | 45.35 | 6.47 | 0.75% |
| Cipla Ltd | 28.51 | 4.38 | 0.89% |
| Torrent Pharmaceuticals Ltd | 68.45 | 16.54 | 0.84% |
Price Comparison
Compare GLAXO with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding GlaxoSmithKline Pharmaceuticals Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Kotak Equity Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.6653% | Percentage of the fund’s portfolio invested in the stock 1.05% | Change in the portfolio weight of the stock over the last 3 months 0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 51/73 (-6) |
Aditya Birla Sun Life ELSS Tax Saver Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5752% | Percentage of the fund’s portfolio invested in the stock 1.44% | Change in the portfolio weight of the stock over the last 3 months -0.20% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 16/74 (-1) |
SBI FUNDS MANAGEMENT PVT LTD#SBI MF-SBI MAGNUM MIDCAP FUND DIRECT PL GROWTH Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5673% | Percentage of the fund’s portfolio invested in the stock 1.04% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 26/82 (-6) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
Dividend Yield
Current dividend yield is 1.37%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹13.74 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateNov 7, 2024
Dividend/Share
₹12.00
Ex DateEx Date
Nov 7, 2024
Cash Dividend
Ex DateEx DateMay 31, 2024
Dividend/Share
₹32.00
Ex DateEx Date
May 31, 2024
Cash Dividend
Ex DateEx DateJun 30, 2023
Dividend/Share
₹32.00
Ex DateEx Date
Jun 30, 2023
Cash Dividend
Ex DateEx DateJul 7, 2022
Dividend/Share
₹60.00
Ex DateEx Date
Jul 7, 2022
Cash Dividend
Ex DateEx DateJul 7, 2022
Dividend/Share
₹30.00
Ex DateEx Date
Jul 7, 2022
Net profit of Glaxosmithkline Pharmaceuticals rose 16.09% to Rs 252.50 crore in the quarter ended September 2024 as against Rs 217.51 crore during the previous quarter ended September 2023. Sales rose 5.62% to Rs 1010.77 crore in the quarter ended September 2024 as against Rs 956.99 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales1010.77956.99 6 OPM %31.8330.25 - PBDT355.98317.27 12 PBT339.12299.16 13 NP252.50217.51 16 Powered by Capital Market - Live
GlaxoSmithKline Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 29 October 2024, has recommended a Special Interim dividend of Rs.12 per share (i.e.120%), subject to the approval of the shareholders.Powered by Capital Market - Live
GlaxoSmithKline Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 29 October 2024.Powered by Capital Market - Live
Glaxosmithkline Pharmaceuticals consolidated net profit rises 37.87% in the June 2024 quarter
Net profit of Glaxosmithkline Pharmaceuticals rose 37.87% to Rs 182.33 crore in the quarter ended June 2024 as against Rs 132.25 crore during the previous quarter ended June 2023. Sales rose 6.96% to Rs 814.65 crore in the quarter ended June 2024 as against Rs 761.66 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales814.65761.66 7 OPM %28.3018.89 - PBDT265.81180.04 48 PBT249.40163.68 52 NP182.33132.25 38 Powered by Capital Market - Live
GSK Pharma Q1 PAT climbs 39% YoY to Rs 182 crore
Revenue from operations grew by 9.89% year on year (YoY) to Rs 811 crore during the quarter ended June 2024. Profit before exceptional item and tax was at Rs 248.49 crore in the June 2024 quarter, up 53.95% from Rs 161.41 crore recorded in corresponding quarter last year. Total expenses declined 2.45% to Rs 598.36 crore in Q1 FY25 over Q1 FY24. Cost of materials consumed was at Rs 133.33 crore (down 8.35% YoY) while employee benefits expense stood at Rs 151.28 crore (down 8.32% YoY) during the period under review. The drug maker stated that it continued to deliver a strong growth of 10% with key brands such as Calpol, Augmentin, T-Bact and gaining market share. In addition, the respiratory portfolio comprising Nucala and Trelegy delivered a growth of 57% by further improving access to more patients. The paediatric vaccine segment maintained market leadership in the self-pay private market and delivered double-digit growth of 15%. In the adult vaccines segment, GSK continues to build on the momentum from the launch of Shingrix Herpes Zoster Vaccine (recombinant, adjuvanted) to further expand the adult immunisation category in India through its innovative go-to-market (GTM) strategies, stated the pharmaco. Bhushan Akshikar, managing director, GlaxoSmithKline Pharmaceuticals, said, 'We continue our growth momentum across General Medicines and Vaccines portfolios while maintaining profitability. As we celebrate hundred years of our operations in India, we remain committed to pursuing new growth opportunities, enhancing our leadership in key therapeutic areas and advancing our innovative omnichannel strategies to further enhance customer experience.' GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies. The scrip closed 2.49% higher at Rs 2,824.45 on Friday, 2 August 2024. Powered by Capital Market - Live
GSK Pharma Q1 results: Net profit rises 37%, revenue up 6.9%
GSK Pharmaceuticals Q1 results: Net profit jumps 38% to Rs 182.33 crore
Technical Breakout Stocks: Budget Day volatility! Suzlon, GlaxoSmithkline Pharma and Federal Bank hit fresh 52-week highs - Market Outlook
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 1.86%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.49% to 0.95%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 5.78%, vs industry avg of 15.27%